Non-coding RNAs and estrogen receptor signaling in breast cancer: Nanotechnology-based therapeutic approaches

Amer Al Ali; Tareg M Belali; Mohammed H Abu-Alghayth; Yara Alyahyawi; Adil Abalkhail; Ali Hazazi; Somia A Nassar; Farhan R Khan; Humood Al Shmrany; Shoaeb Mohammad Syed

doi:10.1016/j.prp.2024.155568

Non-coding RNAs and estrogen receptor signaling in breast cancer: Nanotechnology-based therapeutic approaches

Pathol Res Pract. 2024 Aug 29:263:155568. doi: 10.1016/j.prp.2024.155568. Online ahead of print.

Authors

Affiliations

¹ Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, University of Bisha, 255, Al Nakhil, Bisha 67714, Saudi Arabia.
² Department of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, P.O. Box 255, Bisha 67714, Saudi Arabia.
³ Department of Medical Laboratory Technology, College of Nursing and Health Sciences, Jazan University, Jazan, Saudi Arabia.
⁴ Department Public Health, College of Applied Medical Sciences, Qassim University, Buraydah 51452, P.O. Box 6666, Saudi Arabia.
⁵ Department of Pathology and Laboratory Medicine, Security Forces Hospital Program, Riyadh, Saudi Arabia; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
⁶ Department of Laboratory Medical Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Saudi Arabia; Department of Parasitology & Animal Diseases, National Research Centre, 33 Bohouth St., Dokki, Giza 12622, Egypt.
⁷ Department of Clinical Laboratory Science, College of Applied Medical Sciences, Al- Quwayiyah, Shaqra University, Riyadh, Saudi Arabia.
⁸ Department of Laboratory Medical Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Saudi Arabia. Electronic address: [email protected].
⁹ Department of Pharmaceutics, Dayanand College of Pharmacy, Barshi Road, Latur, MS, 413531, India. Electronic address: [email protected].

PMID: 39288475
DOI: 10.1016/j.prp.2024.155568

Abstract

This review investigates the regulatory role of non-coding RNAs (ncRNAs) in estrogen receptor (ER) signaling pathways, particularly in the context of breast cancer therapy, with an emphasis on the emerging potential of nanotechnology for drug delivery. The information was obtained from reputable databases, including PubMed, Elsevier, Springer, Wiley, Taylor, and Francis, which contain past and present research. Breast cancer remains the most prevalent cancer among women worldwide, and ER signaling mechanisms heavily influence its progression. Treatment options have traditionally encompassed surgery, chemotherapy, radiation therapy, targeted therapy, and hormone therapy. In recent decades, nanomedicine has emerged as a promising approach to breast cancer treatment. By passively targeting tumor cells and reducing toxicity, nanodrugs can overcome the challenges of conventional chemotherapy. Additionally, nanocarriers can stimulate tumor cells, enhancing treatment efficacy. Recent advancements in nanomedicine offer promising approaches for targeted cancer therapy, potentially overcoming the limitations of conventional treatments. This review explores the interactions between long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) with ER pathways, their impact on breast cancer progression, and how these interactions can be leveraged to enhance therapeutic efficacy through nanotechnology-based drug delivery systems.

Keywords: Breast cancer; LncRNA; Nanoparticles; miRNA.

Publication types

Review